The global drug industry is going through a big change. Companies no longer depend only on labs and scientists. They now also depend on smart technology. One of the biggest steps in this direction has come from Novo Nordisk.
Novo Nordisk has announced a partnership with OpenAI. This deal focuses on the use of artificial intelligence, also called AI. The goal is to improve how new medicines are found, tested, and produced.
This move did not happen in isolation. It came soon after its main rival, Eli Lilly and Company, made its own AI deal. This shows that the competition between these companies has entered a new stage. Now, it is not just about drugs. It is also about technology.
Novo Nordisk and Eli Lilly are leaders in medicines for diabetes and weight loss. Their drugs have changed the lives of many people around the world. These medicines are in high demand, especially with the rise in obesity cases.
However, things have changed in recent times. Eli Lilly has moved ahead in many ways. In 2025, it became the first healthcare company to reach a market value of more than $1 trillion. This shows how strong its position has become.
On the other hand, Novo Nordisk has faced some problems. Its stock price has dropped over the past year. Investors have become worried about slower growth and stronger competition.
The pressure increased even more when Eli Lilly got approval for a new oral weight-loss drug. This gave it an extra advantage. Novo Nordisk needed a strong response, and this AI partnership is part of that response.
The deal between Novo Nordisk and OpenAI is very wide. It is not limited to one department. It covers research, production, supply systems, and even office work.
One of the biggest benefits of AI is that it can study large amounts of data very fast. In drug research, there is a huge amount of data. Scientists need to study this data to find new treatments. AI can help them do this much faster than before.
This means new drug ideas can come earlier. It can also help in better planning of clinical trials. Trials are very important because they test if a drug is safe and works well. Faster and better trials can save time and money.
Some early projects have already started inside the company. Full use of these AI tools is expected by the end of 2026.
Another important part of this deal is training. Novo Nordisk wants its workers to understand and use AI tools. This includes scientists, managers, and other staff.
The goal is not to remove jobs. Instead, the aim is to make work easier and faster. With AI support, employees can focus more on important tasks. Routine work can become simpler.
This step also prepares the company for the future. As AI becomes more common, workers need new skills. This training helps them stay ready.
The stock market reacted in a positive way to this news. After the announcement, Novo Nordisk shares went up by about 2.8% to 3.6%. This shows that investors believe the company is taking the right step.
The interest in AI across the drug industry is also growing very fast. Reports show that AI partnerships in this sector increased by around 120% between 2024 and 2025.
This sharp rise shows that many companies now see AI as a key tool. It is no longer just an experiment. It has become an important part of business strategy.
Novo Nordisk is not alone in this move. Many other big drug companies are also working with AI firms. The goal is similar for all. They want faster research, lower costs, and better results.
Eli Lilly has already made strong progress in this area. Other companies like Novartis and Sanofi have also started their own AI projects.
Experts say that AI has not yet created completely new blockbuster drugs by itself. However, it has helped improve speed and accuracy in many processes. This itself is a big advantage in a competitive market.
This partnership is part of a larger plan by Novo Nordisk. The company wants to return to a stronger position. In recent years, it has made changes to its structure and invested in new technology.
AI can help in many ways. It can reduce the time needed to develop a drug. It can improve supply systems. It can also help leaders make better decisions using data.
All these improvements can lead to better results for both the company and patients.
Even though AI has many benefits, it also brings challenges. One major issue is data safety. Medical data is very sensitive. Companies must protect it carefully.
There are also strict rules in the healthcare sector. AI systems must follow these rules. This can take time and effort.
Another challenge is accuracy. AI depends on data. If the data is not good, the results may not be correct. So, companies must make sure they use high-quality data.
Trust is also important. Doctors and regulators must feel confident about AI use. This trust builds slowly over time.
The partnership between Novo Nordisk and OpenAI shows a clear direction for the future. Technology and medicine are becoming closely connected.
As competition with Eli Lilly continues, the smart use of AI may decide who leads the market. Speed and better decision-making will play a big role.
The full effect of this deal will become clear by 2026. If it works well, it may change how drugs are made across the world.
In the coming years, AI may become just as important as the medicines themselves.